Clinical Trial Update: Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update examining dermatologic effects from subcutaneous injections of ISIS 113715 in participants with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ISIS 113715

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED